ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements with these filters
Entero's subsidiary Vasavi Medicare faces an INR 11.87 crore customer default. Vasavi has fully provided for the dues and plans legal recovery action.
Q2FY27 revenue Rs 2,087 Cr (+32.9% reported, +34.7% LFL), EBITDA Rs 111 Cr at 5.3% margin, PAT Rs 61 Cr (+66%). Strategy: consolidate fragmented distribution and scale MedTech (IVD, cardio-ortho).
Entero Healthcare Solutions Ltd reported revenue from operations of ₹2,087 Cr (+32.9% YoY) and net profit of ₹60.7 Cr (+65.8% YoY) for Q2 FY27.
Entero Healthcare Solutions filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing reports promoter and public holdings, with no transaction or corporate event.
Entero Healthcare Solutions scheduled a board meeting for November 04, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026.
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 2026.
Entero Healthcare allotted 43,155 equity shares to employees upon exercise of stock options. The total consideration amounts to ₹4.24 Crore.
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Prasid Uno Family Trust acquired 10,88,500 shares (2.50%) of Entero Healthcare Solutions Ltd via a block deal. Post-transaction, their total stake is 6.93%.
Entero Healthcare Solutions announced the completion of the tenure of Non-Executive Independent Director Mr. Rajesh Shashikant Dalal, effective from August 24, 2026.
Entero Healthcare Solutions Ltd held its 8th Annual General Meeting on August 19, 2026. Members approved all resolutions, including financial statement adoption and director re-appointments.
Entero Healthcare Solutions Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended December 31, 2025.
Entero delivered a strong Q1 FY27 with 38.2% revenue growth and hit its full-year EBITDA margin target of 5% in the first quarter itself, signaling rapid structural margin expansion.
Q1FY27 revenue grew 38.2% YoY to ₹1,940.5 Cr with significant margin expansion. Strategy focuses on MedTech scaling and consolidating India's fragmented pharmaceutical distribution market.
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,940 Cr (+38.2% YoY) and net profit of ₹52.1 Cr (+72.5% YoY) for Q1 FY27.
Entero Healthcare incorporated Qurovia Lifesciences as a step-down subsidiary. The company invested Rs. 1 Lakh for the subscription of equity shares.
Entero Healthcare Solutions Ltd has filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ending March 31, 2026.
Entero Healthcare Solutions Ltd has submitted an updated Annual Report for the financial year 2025-26, correcting an error in Note 52 of the Consolidated Financial Statements.
Entero Healthcare Solutions Limited has scheduled a board meeting for August 07, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Entero Healthcare Solutions has filed its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report provides detailed disclosures on its ESG performance.
Entero Healthcare Solutions Limited announced its 8th Annual General Meeting to be held on August 19, 2026, via video conferencing. The annual report is also available.
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details the distribution of equity shares among promoters and public shareholders.
Mr. Rajesh Shashikant Dalal will cease to be a Non-Executive Independent Director from August 24, 2026. He decided not to seek re-appointment after his first term.
Entero Healthcare re-appointed Sandhya Gadkari Sharma and Rajesh Shashikant Dalal as Independent Directors. Both appointments are for a term of 48 months effective June 26, 2026.
Entero Healthcare approved the allotment of 1,475 equity shares under its ESOP 2023. The board also approved re-appointments of two independent directors.
Mr. Kevin Daftary resigned as Nominee Director due to increased commitments. The vacancy will be filled upon a fresh nomination from the trust.
Entero Healthcare allotted 3,420 equity shares under its ESOP Plan 2023 and granted 17,500 fresh options. The move aligns employee incentives with shareholder value.
Entero delivered solid FY26 results, meeting all guidance parameters. Management transitions focus toward organic growth and margin expansion through technology-led scaling and higher-margin MedTech distribution.